Our previous research demonstrated that the Wenxia Changfu Formula(WCF),as a neoadjuvant therapy,inhibits M2 macrophage infiltration in the tumor microenvironment and prevents lung cancer metastasis.Given tumor-associ...Our previous research demonstrated that the Wenxia Changfu Formula(WCF),as a neoadjuvant therapy,inhibits M2 macrophage infiltration in the tumor microenvironment and prevents lung cancer metastasis.Given tumor-associated macrophages(TAMs)in epithelial-mesenchymal transition(EMT),this study investigated whether WCF impedes lung cancer metastasis by attenuating TAM-induced EMT in non-small cell lung cancer(NSCLC)cells.Utilizing a co-culture model treated with or without WCF,we observed that WCF downregulated cluster of differentiation 163(CD163)expression in macrophages,reduced CCL18 levels in the conditioned medium,and inhibited the growth,invasion,and EMT of NSCLC cells induced by macrophage co-culture.Manipulation of CCL18 levels and Src overexpression in NSCLC cells revealed that WCF’s effects are mediated through CCL18 and Src signaling.In vivo,WCF inhibited recombinant CCL18(rCCL18)-induced tumor metastasis in nude mice by blocking Src signaling.These findings indicate that WCF inhibits NSCLC metastasis by impeding TAM-induced EMT via antagonistic modulation of CCL18,providing evidence for its potential development and clinical application in NSCLC patients.展开更多
Objective： To explore the apoptosis mechanism of Wenxia Changfu Formula （温下肠腑方, WCF） in reversing drug resistance of lung cancer in vivo. Metbods： Thirty model mice were randomly assigned to three groups： co...Objective： To explore the apoptosis mechanism of Wenxia Changfu Formula （温下肠腑方, WCF） in reversing drug resistance of lung cancer in vivo. Metbods： Thirty model mice were randomly assigned to three groups： control group, cisplatin （CDDP） group, and WCF group. A transplanted tumor model of lung adenocarcinoma was established in all groups. Mice in the WCF group received intragastric administration of WCF （0.2 mL/10 g body weight） everyday in addition to CDDP intraperitoneally （5 mg/kg body weight） twice a week. The mice in the CDDP group received CDDP intraperitoneally （5 mg/kg body weight） twice a week, while the control group received normal saline intraperitoneally （0.2 mL/10 g body weight） everyday. The weight of the nude mice and respective tumors, tumor volume and tumor-inhibiting rate were measured. Electron microscopy was used to observe the existence of apoptosis body. Apoptosis index （AI） was detected by TdT-mediated dUTP nick end labeling staining. The expression of Fas and FasL mRNA was investigated by reverse transcription polymerase chain reaction, while immunohistochemistry was applied to detect the protein expression of Fas and FasL, caspase-3 and caspase-activated DNase （CAD）, respectively. Results： Compared with CDDP group and control group, WCF could significantly reduce the tumor volume from the 19th day and alleviate the tumor weight （P〈0.05）, and the apoptosis body was found in tumor cells in the WCF group. WCF could also enhance the level of AI, up-regulate the expression of caspase apoptosis pathway related protein caspase-3 and CAD, as well as the expression of Fas, FasL mRNA and protein （P〈0.05）. Conclusion： WCF could improve the sensitivity of tumor cells to CDDP and reverse the drug resistance by inducinq the apoptosis.展开更多
Objective： To observe the effect of the combination of Wenxia Changfu Formula （温下肠腑方, WCF） with cisplatin （CDDP） on inhibiting non-small cell lung cancer （NSCLC） in vitro and in vivo and explore its mechan...Objective： To observe the effect of the combination of Wenxia Changfu Formula （温下肠腑方, WCF） with cisplatin （CDDP） on inhibiting non-small cell lung cancer （NSCLC） in vitro and in vivo and explore its mechanism from its effect on cell cycle. Methods： In vitro, WCF-containing serum was prepared and the rhubarb bl, emodin, and aconitine were detected qualitatively by high-performance liquid chromatogram （HPLC）. A549 cell lines were treated with blank control （dimethyl sulfoxide）, normal serum, normal serum with CDDP （1.25, 2.5, and 5.0 μg/mL, respectively）, WCF-containing serum plus different doses of CDDP （1.25, 2.5, and 5.0 μ g/mL, respectively）. The inhibitory effect was detected by 3-（4,5）-dimethylthiazo（-z- yl）-3,5-diphenylterazolium bromide （MI-I）. The cell cycle was detected by flow cytometry. The protein and mRNA expressions of cyciin D1, proliferating cell nuclear antigen （PCNA）, retinoblastoma （Rb）, and p16 were observed with immunofluorescence and RT-PCR, respectively. In vivo, nude mice xenograft model was established and grouped into the control, CDDP, WCF, and combination groups. The combination＇s inhibition of tumor growth and influence on the weight, spleen, and thymus gland were observed. Results： The inhibitory rate of the combination against A549 cell lines excelled the CDDP alone significantly （P〈0.05）; the combination showed a synergism inhibitory effect （Q=1.19）. Compared with the monotherapy, the combination increased the cell percentage in G0/G1 phase and decreased the cell percentage in S phase significantly （P〈0.05）; the protein and mRNA expressions of cyclin D1, PCNA, and Rb were significantly reduced; the protein and mRNA expressions of p16 were significantly enhanced. Compared with the monotherapy, the combination inhibited the tumor growth significantly in vivo and reduced the weight of tumor （P〈0.05）; compared with the CDDP group, the spleen and thymus gland index of the combination group were enhanced significantly （P〈0.05）. Conclusions： The combination of WCF with CDDP significantly inhibited the A549 cell lines proliferation in vitro and the growth of the tumor in vivo; it inhibited effectively the atrophy of the immune organ caused by chemotherapy. The combination inhibited overproliferation of A549 cell lines by arresting the Go/G1 phase of cell cycle and affecting the protein and mRNA expressions of cell cycle-related proteins, cyclin D1, etc.展开更多
Background A multi-center large scale study is needed to confirm the efficacy and safety of domestic peritoneal dialysis （PD） solutions. Some researchers believe that 6 Lid is enough for adequate dialysis, but there...Background A multi-center large scale study is needed to confirm the efficacy and safety of domestic peritoneal dialysis （PD） solutions. Some researchers believe that 6 Lid is enough for adequate dialysis, but there is no multi-center prospective study on Chinese population to confirm this. In this study, we evaluated the efficacy and safety of domestic PD solution （Changfu） and its difference between 6 L and 8 L dosage. Methods Adult PD patients who had taken PD therapy for at least one month were selected and divided into four groups according to two dialysis solution brands and two dialysis dosages, i.e., 6 L dose with Changfu dialysis solution, 6 L dose with Baxter dialysis solution, 8 L dose with Changfu dialysis solution, and 8 L dose with Baxter dialysis solution. After 48 weeks, the changes of primary and secondary efficacy indices were compared between different types and different dosages. We also analyzed the changes of safety indices. Results Changes of Kt/V from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of creatinine clearance rate （Ccr）. Normalized protein catabolic rate （nPCR） from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of net ultrafiltration volume （nUF） and estimated glomerular filtration rate （eGFR）. Changes of nPCR from baseline to 48 weeks between 6 L and 8 L showed no statistical differences; so did those of nUF and eGFR. The decline of Kt/V from baseline to 48 weeks in 6 L group was more than that in 8 L group. Change of Ccr was similar. During the 48-week period, the mean Kt/V was above 1.7/w, and mean Ccr was above 50 L.1.73 m-2.w1. More adverse events were found in Changfu group before Changfu Corporation commenced technology optimization, and the statistical differences disappeared after that. Conclusions The domestic PD solution （Changfu） was proven to be as effective as Baxter dialysis solution. During 48- week period, a dosage of 6 L/d was enough for these patients to reach adequate PD. Clinical study promotes technological optimization, further helps to improve the safety indices of the medical products.展开更多
基金supported by the National Natural Science Foundation of China(No.82274406,81774198)Zhejiang Provincial Natural Science Foundation of China(No.LZ24H270001)the Postgraduate Scientific Research Fund of Zhejiang Chinese Medical University(No.2022YKJ14).
文摘Our previous research demonstrated that the Wenxia Changfu Formula(WCF),as a neoadjuvant therapy,inhibits M2 macrophage infiltration in the tumor microenvironment and prevents lung cancer metastasis.Given tumor-associated macrophages(TAMs)in epithelial-mesenchymal transition(EMT),this study investigated whether WCF impedes lung cancer metastasis by attenuating TAM-induced EMT in non-small cell lung cancer(NSCLC)cells.Utilizing a co-culture model treated with or without WCF,we observed that WCF downregulated cluster of differentiation 163(CD163)expression in macrophages,reduced CCL18 levels in the conditioned medium,and inhibited the growth,invasion,and EMT of NSCLC cells induced by macrophage co-culture.Manipulation of CCL18 levels and Src overexpression in NSCLC cells revealed that WCF’s effects are mediated through CCL18 and Src signaling.In vivo,WCF inhibited recombinant CCL18(rCCL18)-induced tumor metastasis in nude mice by blocking Src signaling.These findings indicate that WCF inhibits NSCLC metastasis by impeding TAM-induced EMT via antagonistic modulation of CCL18,providing evidence for its potential development and clinical application in NSCLC patients.
基金Supported by the National Natural Science Foundation of China(No.81072832,81273634)the Opening Project of Shanghai Key Laboratory of Complex Prescription(No.11DZ2272300)National Science and Technology Major Projects for"Major New Drugs Innovation and Development(No.2010Z0940)
文摘Objective： To explore the apoptosis mechanism of Wenxia Changfu Formula （温下肠腑方, WCF） in reversing drug resistance of lung cancer in vivo. Metbods： Thirty model mice were randomly assigned to three groups： control group, cisplatin （CDDP） group, and WCF group. A transplanted tumor model of lung adenocarcinoma was established in all groups. Mice in the WCF group received intragastric administration of WCF （0.2 mL/10 g body weight） everyday in addition to CDDP intraperitoneally （5 mg/kg body weight） twice a week. The mice in the CDDP group received CDDP intraperitoneally （5 mg/kg body weight） twice a week, while the control group received normal saline intraperitoneally （0.2 mL/10 g body weight） everyday. The weight of the nude mice and respective tumors, tumor volume and tumor-inhibiting rate were measured. Electron microscopy was used to observe the existence of apoptosis body. Apoptosis index （AI） was detected by TdT-mediated dUTP nick end labeling staining. The expression of Fas and FasL mRNA was investigated by reverse transcription polymerase chain reaction, while immunohistochemistry was applied to detect the protein expression of Fas and FasL, caspase-3 and caspase-activated DNase （CAD）, respectively. Results： Compared with CDDP group and control group, WCF could significantly reduce the tumor volume from the 19th day and alleviate the tumor weight （P〈0.05）, and the apoptosis body was found in tumor cells in the WCF group. WCF could also enhance the level of AI, up-regulate the expression of caspase apoptosis pathway related protein caspase-3 and CAD, as well as the expression of Fas, FasL mRNA and protein （P〈0.05）. Conclusion： WCF could improve the sensitivity of tumor cells to CDDP and reverse the drug resistance by inducinq the apoptosis.
基金Supported by the National Natural Science Foundation of China (No.81072832N0.30873222)Shandong Provincial Young and Middle-aged Scientists(No.2008BS03010)
文摘Objective： To observe the effect of the combination of Wenxia Changfu Formula （温下肠腑方, WCF） with cisplatin （CDDP） on inhibiting non-small cell lung cancer （NSCLC） in vitro and in vivo and explore its mechanism from its effect on cell cycle. Methods： In vitro, WCF-containing serum was prepared and the rhubarb bl, emodin, and aconitine were detected qualitatively by high-performance liquid chromatogram （HPLC）. A549 cell lines were treated with blank control （dimethyl sulfoxide）, normal serum, normal serum with CDDP （1.25, 2.5, and 5.0 μg/mL, respectively）, WCF-containing serum plus different doses of CDDP （1.25, 2.5, and 5.0 μ g/mL, respectively）. The inhibitory effect was detected by 3-（4,5）-dimethylthiazo（-z- yl）-3,5-diphenylterazolium bromide （MI-I）. The cell cycle was detected by flow cytometry. The protein and mRNA expressions of cyciin D1, proliferating cell nuclear antigen （PCNA）, retinoblastoma （Rb）, and p16 were observed with immunofluorescence and RT-PCR, respectively. In vivo, nude mice xenograft model was established and grouped into the control, CDDP, WCF, and combination groups. The combination＇s inhibition of tumor growth and influence on the weight, spleen, and thymus gland were observed. Results： The inhibitory rate of the combination against A549 cell lines excelled the CDDP alone significantly （P〈0.05）; the combination showed a synergism inhibitory effect （Q=1.19）. Compared with the monotherapy, the combination increased the cell percentage in G0/G1 phase and decreased the cell percentage in S phase significantly （P〈0.05）; the protein and mRNA expressions of cyclin D1, PCNA, and Rb were significantly reduced; the protein and mRNA expressions of p16 were significantly enhanced. Compared with the monotherapy, the combination inhibited the tumor growth significantly in vivo and reduced the weight of tumor （P〈0.05）; compared with the CDDP group, the spleen and thymus gland index of the combination group were enhanced significantly （P〈0.05）. Conclusions： The combination of WCF with CDDP significantly inhibited the A549 cell lines proliferation in vitro and the growth of the tumor in vivo; it inhibited effectively the atrophy of the immune organ caused by chemotherapy. The combination inhibited overproliferation of A549 cell lines by arresting the Go/G1 phase of cell cycle and affecting the protein and mRNA expressions of cell cycle-related proteins, cyclin D1, etc.
文摘Background A multi-center large scale study is needed to confirm the efficacy and safety of domestic peritoneal dialysis （PD） solutions. Some researchers believe that 6 Lid is enough for adequate dialysis, but there is no multi-center prospective study on Chinese population to confirm this. In this study, we evaluated the efficacy and safety of domestic PD solution （Changfu） and its difference between 6 L and 8 L dosage. Methods Adult PD patients who had taken PD therapy for at least one month were selected and divided into four groups according to two dialysis solution brands and two dialysis dosages, i.e., 6 L dose with Changfu dialysis solution, 6 L dose with Baxter dialysis solution, 8 L dose with Changfu dialysis solution, and 8 L dose with Baxter dialysis solution. After 48 weeks, the changes of primary and secondary efficacy indices were compared between different types and different dosages. We also analyzed the changes of safety indices. Results Changes of Kt/V from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of creatinine clearance rate （Ccr）. Normalized protein catabolic rate （nPCR） from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of net ultrafiltration volume （nUF） and estimated glomerular filtration rate （eGFR）. Changes of nPCR from baseline to 48 weeks between 6 L and 8 L showed no statistical differences; so did those of nUF and eGFR. The decline of Kt/V from baseline to 48 weeks in 6 L group was more than that in 8 L group. Change of Ccr was similar. During the 48-week period, the mean Kt/V was above 1.7/w, and mean Ccr was above 50 L.1.73 m-2.w1. More adverse events were found in Changfu group before Changfu Corporation commenced technology optimization, and the statistical differences disappeared after that. Conclusions The domestic PD solution （Changfu） was proven to be as effective as Baxter dialysis solution. During 48- week period, a dosage of 6 L/d was enough for these patients to reach adequate PD. Clinical study promotes technological optimization, further helps to improve the safety indices of the medical products.
